{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T06:27:14Z","timestamp":1648880834102},"reference-count":13,"publisher":"Medwave Estudios Limitada","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medwave"],"DOI":"10.5867\/medwave.2016.6379","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T20:00:30Z","timestamp":1456948830000},"page":"e6379-e6379","source":"Crossref","is-referenced-by-count":0,"title":["Is the addition of aminoglycosides to beta-lactams in cancer patients with febrile neutropenia needed?"],"prefix":"10.5867","volume":"16","author":[{"given":"Valeria","family":"Contreras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Heredia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3888","published-online":{"date-parts":[[2016,2,2]]},"reference":[{"issue":"4","key":"ref0","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1473-3099(02)00241-4","article-title":"Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis.","volume":"2","author":"Furno","year":"2002","unstructured":"Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis. 2002 Apr;2(4):231-42. | PubMed |","journal-title":"Lancet Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1473-3099","issn-type":"print"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"CD003038","DOI":"10.1002\/14651858.cd003038.pub2","article-title":"Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.","volume":"6","author":"Paul","year":"2013","unstructured":"Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013 Jun 29;6:CD003038. | CrossRef | PubMed |","journal-title":"Cochrane Database Syst Rev","ISSN":"http:\/\/id.crossref.org\/issn\/1469-493X","issn-type":"print"},{"key":"ref2","first-page":"1295","article-title":"Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.","volume-title":"39th Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Paul","year":"1999","unstructured":"Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003 May 24;326(7399):1111. | PubMed | Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis. 2001 Oct 15;33(8):1295-301. | PubMed | Del Favero A, Menichetti F, Micozzi A, Bucaneve G, Martino P. Double-blind, randomized clinical trial comparing monotherapy with piperacillin-tazobactam vs. piperacillin-tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA; 1999: 722. | Link | Doyen C, Tepatondele JM, Wauters G, Michaux JL. A randomized therapeutic trial for ceftazidime versus ceftazidime and amikacin in febrile granulopenic patients. International Congress of Chemotherapy (13th : 1983: Vienna: Spitzy KH); 1983: 26-9. | Link | Esteve J, Nomdedeu B, Mensa J, Guardia R, Marco F, Montserrat E. Piperacillin\/tazobactam vs. piperacillin\/tazobactam plus amikacin as empiric therapy for fever in neutropenic patients. Blood. 1997;90(Suppl 1):229b. | Link | Kiehl MG, Bischoff M, Basara N, Guenzelmann S, Fauser A. A prospective randomized trial comparing the efficacy and safety of piperacillin\/tazobactam versus piperacillin\/tazobactam plus netilmicin in the treatment of febrile neutropenia in allogeneic stem cell recipients. Abstracts Of The Interscience Conference On Antimicrobial Agents & Chemotherapy. 2001 2001(41):267. | Link | Kinsey SE, Machin SJ, Goldstone AH. Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. J Hosp Infect. 1990 Apr;15 Suppl A:49-53. | PubMed | Kojima A, Shinkai T, Soejima Y, Okamoto H, Eguchi K, Sasaki Y, et al. A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. Am J Clin Oncol. 1994 Oct;17(5):400-4. | PubMed |"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Marie JP, Pico J, Lapierre V, Maulard C, Pappo M, Chiche D, et al. Comparative trial of ceftazidime alone, ceftazidime + amikacin and ceftazidime + vancomycin as empiric therapy of febrile cancer patients with induced prolonged neutropenia. M\u00e9decine et Maladies Infectieuses. 1991 7;21(7):386-8.","DOI":"10.1016\/S0399-077X(05)80140-4"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Marie JP, Vekhoff A, Pico JL, Guy H, Andremont A, Richet H. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. J Antimicrob Chemother. 1998 Jun;41 Suppl D:57-64. | PubMed |","DOI":"10.1093\/jac\/41.suppl_4.57"},{"key":"ref5","unstructured":"Micozzi A, Bucaneve G, Menichetti F, Martino P, Del Favero A, Program GI. Double blind, randomized, clinical trial comparing monotherapy with piperacillin-tazobactam versus piperacillin-tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. Supportive care in cancer. 2000;8 (Suppl:160). | Link |"},{"issue":"4","key":"ref6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF01703442","article-title":"Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients.","volume":"63","author":"Nov\u00e1kov\u00e1","year":"1991","unstructured":"Nov\u00e1kov\u00e1 IR, Donnelly JP, de Pauw BE. Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. Ann Hematol. 1991 Oct;63(4):195-200. | PubMed |","journal-title":"Ann Hematol","ISSN":"http:\/\/id.crossref.org\/issn\/0939-5555","issn-type":"print"},{"key":"ref7","first-page":"146","article-title":"Ceftazidime (CFZ) monotherapy as empirical initial treatment of febrile neutropenia cancer patients (Pts).","volume":"7","author":"Papachristodoulou","year":"1996","unstructured":"Papachristodoulou A, Vaslamatzis M, Xynogalos S, Papacharalambous A, Alexopoulos CG. Ceftazidime (CFZ) monotherapy as empirical initial treatment of febrile neutropenia cancer patients (Pts). Ann of Oncol. 1996;7(suppl 5):146. | CrossRef |","journal-title":"Ann Oncol","ISSN":"http:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"},{"issue":"6","key":"ref8","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1128\/AAC.26.6.870","article-title":"Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia.","volume":"26","author":"Piccart","year":"1984","unstructured":"Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984 Dec;26(6):870-5. | PubMed |","journal-title":"Antimicrob Agents Chemother","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"issue":"2","key":"ref9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/archinte.1992.00400140037010","article-title":"A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.","volume":"152","author":"Rolston","year":"1992","unstructured":"Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992 Feb;152(2):283-91. | PubMed |","journal-title":"Arch Intern Med","ISSN":"http:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1086\/383046","article-title":"Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.","volume":"39","author":"Tamura","year":"2004","unstructured":"Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A, Ohyashiki K, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S15-24. | PubMed |","journal-title":"Clin Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1058-4838","issn-type":"print"},{"issue":"4","key":"ref11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ajh.10236","article-title":"Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.","volume":"71","author":"Tamura","year":"2002","unstructured":"Tamura K, Matsuoka H, Tsukada J, Masuda M, Ikeda S, Matsuishi E, et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol. 2002 Dec;71(4):248-55. | PubMed |","journal-title":"Am J Hematol","ISSN":"http:\/\/id.crossref.org\/issn\/0361-8609","issn-type":"print"},{"issue":"4","key":"ref12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.","volume":"52","author":"Wrzesie\u0144-Ku\u015b","year":"2011","unstructured":"Wrzesie\u0144-Ku\u015b A, Jamroziak K, Wierzbowska A, Robak T. Cefepime in monotherapy or in combination with amikacine as the empirical treatment of febrile neutropenic patients. Acta Haematologica Polonica. 2001;32(2):165-72. | Link | Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 Feb 15;52(4):427-31. | CrossRef | PubMed |","journal-title":"Clin Infect Dis","ISSN":"http:\/\/id.crossref.org\/issn\/1058-4838","issn-type":"print"}],"container-title":["Medwave"],"original-title":["\u00bfEs necesario agregar aminoglic\u00f3sidos al tratamiento con betalact\u00e1micos en pacientes con c\u00e1ncer y neutropenia febril?"],"link":[{"URL":"https:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T05:35:17Z","timestamp":1567661717000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,2]]},"references-count":13,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2016,2,2]]}},"URL":"https:\/\/doi.org\/10.5867\/medwave.2016.6379","relation":{},"ISSN":["0717-6384"],"issn-type":[{"value":"0717-6384","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,2]]}}}